Vanda's Nereus Pill: Because VR Devs' Motion Sickness Code Needs a Commit Without the Puke

Vanda Pharmaceuticals Inc. (VNDA) presented at the 44th Annual J.P. Morgan Healthcare Conference, held on January 15, 2026, at 12:00 PM EST, where Kevin Moran, Senior Vice President, Chief Financial Officer, and Treasurer, provided an overview of the company's innovation-led strategy and commercial portfolio. The company, which is dedicated to innovating in the service of people's pursuit of happiness, has a decades-long track record of successfully developing and commercializing innovative therapies, with a current portfolio anchored by 4 FDA-approved brands: Fanapt, an atypical antipsychotic; HETLIOZ, approved for 2 orphan sleep disorders; PONVORY, approved in the neurology space for multiple sclerosis; and NEREUS, recently approved for vomiting induced by motion. As stated by Kevin Moran, Vanda Pharmaceuticals has a strong debt-free balance sheet, providing substantial capital to invest in upcoming R&D and commercial activities, with a late-stage growth pipeline targeting significant unmet needs in billion-dollar markets. The presentation, moderated by Bhavana Balakrishnan, Associate in the Healthcare Investment Banking Group, highlighted the company's numerous imminent regulatory catalysts, including the recent approval of NEREUS, and its robust financial position, with a focus on driving growth and innovation in the biopharmaceutical industry. With its robust pipeline and commercial portfolio, Vanda Pharmaceuticals is well-positioned to address significant unmet needs in the market, driven by its commitment to innovation and patient-centric approach, as evident from its participation in the prestigious J.P. Morgan Healthcare Conference.